Loading clinical trials...
Loading clinical trials...
A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Dose Escalating Study to Evaluate the Safety and Tolerability of Topically Applied Bisphosphocin Nu-3 Gel to Clinically Noninfected Chronic Diabetic Foot Ulcers (cDFU)
Conditions
Interventions
5% Bisphosphocin Topical Gel
Placebo Topical Gel
+1 more
Locations
5
United States
NEA Baptist Clinic
Jonesboro, Arkansas, United States
Limb Preservation Platform, Inc.
Fresno, California, United States
Doctors Research Network
South Miami, Florida, United States
ACM Global Laboratories
Rochester, New York, United States
Futuro Clinical Trials, LLC
McAllen, Texas, United States
Start Date
March 11, 2022
Primary Completion Date
May 18, 2022
Completion Date
June 15, 2022
Last Updated
January 30, 2024
Lead Sponsor
Lakewood-Amedex Inc
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions